Acemannan as a Vaccine Adjuvant: A Forgotten Chapter in Veterinary Medicine

Sensitive Topic Notice: As far as we know the testing on lab animals was employed according to ethical standards, but some might find this disconcerting.

I’m going to cover Acemannan again, but with a slightly different focus this time, with an emphasis on veterinarian vaccines. So let’s look at Carrington Laboratories, Solvay Animal Health, and the diseases–and the vaccines that fight them–that can affect turkeys, chickens, ducks, quail, swine, mice, cats, and dogs. As always this is my invitation to join this effort to dig deeper and reach wider.

Let’s get started, but first I’ll put up a screenshot of the first page of the Carrington Laboratories annual report 1999. From this December 1999, 130-page annual report submitted to the Securities and Exchange Commission, Carrington Laboratories made reference on page 12 of the business relationship it had with Solvay Animal Health, Inc. that started in September 1990. Remember, Carrington Labs discovered Acemannan in 1985. At the time, Solvay was the world’s largest manufacturer of veterinarian vaccines in the world.

The Carrington report records, in September 1990, Carrington Laboratories granted Solvay an exclusive worldwide license to use and sell an adjuvant processed from aloe vera L for poultry disease. In January 1992, Solvay received approval from the USDA to market Acemannan immunostimulant as an adjuvant to a vaccine for Marek’s disease, a virus infection that kills chickens or renders them unfit for human consumption.

As the story I heard goes, Solvay sought out Carrington Labs because Marek’s disease was making a negative impact on the whole of the poultry industry. The Solvay vaccine efforts were only getting around 66% protection. So their vaccine did claim some efficacy, but this meant that some poultry farmers were losing a full third of the chickens they were attempting to raise. This, of course, created a significant economic impact. Something more had to be done.

As was stated in the annual report of Carrington Laboratories, Solvay obtained approval from the USDA in January 1992 to use Acemannan as an adjuvant.

What is an adjuvant? An adjuvant is used in a vaccine to increase the efficacy or potency of vaccines. Well, that’s the short definition. More on that later.

I am going to digress only slightly, but these days, after a large emphasis on human vaccines because of a recent pandemic, more and more people have been doing their due diligence to investigate the vaccine knowledge-base overall. More power to them. This has resulted in not having to go very far to discover things like aluminum. It is also considered an adjuvant that’s commonly used in some human vaccines. Or as other parts of the English-speaking world reference it, aluminium.

Unlike aluminum-based adjuvants, which are added to stimulate inflammation and immune activation, Acemannan is a naturally derived polysaccharide (a natural sugar) extracted from the inner leaf gel of Aloe vera. Rather than being a metal compound, it is a biological molecule that researchers observed could interact with immune cells in a different way not to stimulate but to modulate the immune system. This is the idea that Acemannan only created a better environment for the immune system to do what it does best naturally without toxic stimulation.

I included these comments to create an anchor point so we can better understand the idea of adjavents. We are not looking at vaccines on a human level here, though. We have veterinary medicine looking for an adjuvant, and they decide to use Acemannan during this time. Upon doing so, their 66% protection rate increased to 99%. As Sam Caster put it, “nobody had ever seen anything like it in medicine or anything like it in nature.”

Okay, that’s the anecdote and little extra information to ground us in the science, but that started me digging to want to know more. The description of Acemannan certainly fits the definition of other adjuvants, as the claim here is that adjuvants in general help to boost the body’s immune response to a vaccine, making it stronger and longer lasting. They do this by stimulating the immune system, increasing the production of antibodies, or prolonging the immune response. There, that’s the longer definition.

If you’ve been watching my videos, you know that Acemannan, in regards to its mechanism of action (how it works), only fits this definition loosely; as scientific studies will instead emphasize its immune-modulation capacities and its non-toxic characteristics. Using the word “boost” or “stimulate” is not a good fit for the uniqueness that Acemannan brings to the table. In reality, it is a food-grade substance with remarkable evidence of efficacy.

Solvay did their own due diligence and concluded a great deal of testing and experimentation, indicated in a 93-page international application published under the Patent Corporation Treaty with the World Intellectual Property Organization. They submitted this application in 1993. They titled it, Vaccine Containing Acemannan as an Adjuvant. So that made it pretty clear what this application was all about. Vaccine Containing Acemannan as an Adjuvant. They were making application for a patent, and they referenced their vaccine containing Acemannan as an invention.

From the abstract of the application, it reads:

This invention is about a vaccine for turkeys that uses a weakened version, attenuated is the scientific term, of a herpes virus. This would be in reference to Marek’s disease. The vaccine includes a special ingredient called Acemannan that helps make the immune response stronger. It also has a suitable carrier, which is something used to deliver the vaccine. The invention can also be used to make vaccines for other viruses and bacteria. It’s designed to protect animals, like chicks, from diseases such as Marek’s disease by using similar ingredients and methods.

Before I make further comment of my curation, let me make clear concerning this idea of experimenting on animals, especially among us who want to know, that these scientists did abide by what’s called the CFR, the Code of Federal Regulations. This generally refers to regulations set by the United States Department of Agriculture, the USDA, and its agencies concerning the treatment of animals.

The Solvay patent application is full of complex information for non-scientists like me in 93 pages extracted from nearly 50 experiments on hundreds of laboratory animals, including turkeys, chickens, pigs, and mice. The data from those experiments is revealed in 23 tables which provide the statistics that point to the efficacious contribution of Acemannan in their experimentation on these animals. This is very different than the other studies I have featured on my videos, which are often characterized by one or two experiments on certainly a lesser amount of laboratory specimens and sometimes done so in a petri dish culture. So this 93-page application is most significant. This wasn’t just a single study. It was what it takes to obtain a patent for an invention.

To keep this curation short, I’ll reference some input Solvay provided that points to their claims that Acemannan, quote, promotes the efficacy of a subsequently administered veterinary vaccine. Another difference here is that Acemannan is incorporated into a vaccine program where the scientists are already expecting the vaccines to prove efficacious at least at some measurable level without the Acemannan. This creates a priority focus on Acemannan as all these experiments, studies, and as is indicated in the patent application, is putting Acemannan to the test and with high hopes of affirmative Acemannan-based results. And as we will see, they were not disappointed.

First, let me make this clear. It would not make sense in the scope of an experiment of this nature to fail to challenge the laboratory animal with a virus that the vaccine they gave the animal is designed to intercept. Therefore, reference is made to a challenge given to animal specimens. This would be a reference to viruses given to the vaccinated animals. Some not vaccinated at all and some vaccines with Acemannan added and some without.

As a way to make this clear, I’ll feature table number 8 of the application before giving a synopsis. Many of the tables in the application are much longer, but this one will serve the purpose of both brevity and its bottom line. In this experiment, we see that there are 160 chickens to start, divided into 8 groups of 20. Let’s list the vaccination status groups:

1. Non-vaccinated.
2. Vaccinated with Marek’s disease vaccine as well as Newcastle’s disease vaccine and infectious bronchitis vaccine.
3. Acemannan added as an adjuvant to the Newcastle’s disease and the infectious bronchitis vaccines.
4. Acemannan with the Marek’s disease, Newcastle’s disease, and infectious bronchitis vaccines.

Then they challenged 80 of the chickens with Newcastle disease virus and the other 80 they challenged with infectious bronchitis virus. Understand that the V in NDV and IBV means virus here, not vaccine.

The results? In the unvaccinated group, there was 0% protection in both challenges, meaning all were lost. In group number 2, the NDV had a 65% protection rate and the IBV had an 80% protection rate. So, again, the vaccines displayed efficacy at face value with no Acemannan present. But remember our opening anecdote. Farmers were losing one third of their chickens. That means a 66% protection rate.

Then group number 3 with Acemannan used as an adjuvant, the percent protected went to 85% in the NDV challenge and 100% in the IBV challenge. Then in group number 4, the protection was 90% in the NDV challenge and 85% in the IBV challenge. Here again, in this experiment and throughout the balance of this entire application, is evidence in the words of the Solvay application that Acemannan, given parenterally, promotes the efficacy of a subsequently administered vaccine. Parenterally refers to the administration of substances into the body through routes other than the digestive tract via oral intake. In other words, intravenously (IV: directly into the vein), intramuscularly (IM: injected into a muscle), or subcutaneously (SC or Sub-Q: injected under the skin into fatty tissue).

I’ll place my notes about all the tables 1 through 23 at the end of this video if you want to pause the screens and read them.

And to be clear, this is not an endorsement of vaccines. This is just a study whose focus was on veterinarian vaccines and how they used Acemannan to take their vaccine program to another level of efficacy. But this is just more evidence that Acemannan merits our attention.

The next question I’m sure you want me to answer is, so having applied for an international patent, were they able to acquire it? The answer is yes. The following link will take you to the patent and also to the entire study that I have curated today. https://www.freepatentsonline.com/EP0626008B1.html.

Let it be known that there is an invention made official by the World Patent Office entitled, Vaccine Containing Acemannan as an Adjuvant.

Remember, we market Acemannan products to humans — and to animals if you want — by matching the nutrition we consume with Acemannan that is provided to the malnourished children of the world. Those who consume our products know the benefits of Acemannan and other proprietary products that also improve the lives of the medically fragile globally.

Meanwhile, I hope you will always be careful to maintain good works to meet urgent needs and become heroes to your generation.